ADCT-701

Phase 1Small molecule

ADCT-701 is one of 20 small molecule programs targeting Malignant Peripheral Nerve Sheath Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant Peripheral Nerve Sheath TumorActive, not recruiting

Malignant Peripheral Nerve Sheath TumorPhase 1

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Malignant Peripheral Nerve Sheath Tumor

#DrugCompanyPhaseTrials

Gleevec

Novartis

Phase 3

1 2

Koselugo

AstraZeneca

Phase 2

1 3

Afinitor

Novartis

Phase 2

1 4

Keytruda

Merck & Co.

Phase 2

1 5

Rapamune

PPrism Pharmaceuticals

Phase 2

3 6

Neupogen

EEastern Cooperative Oncology Group

Phase 2

1 7

Ifex

BBaxter Healthcare Corporation

Phase 2

1 8

Adriamycin

GGynecologic Oncology Group

Phase 2

1 9

Vepesid

AAvyxa

Phase 2

1 10

Tazverik

EEpizyme, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1Recruiting

Malignant Peripheral Nerve Sheath Tumor

NCT06041516

Clinical

Trials by Indication[1]

Malignant Peripheral Nerve Sheath Tumor1 trial

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06041516·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ADCT-701. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ADCT-701 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ADCT-701. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNational Cancer Institute (NCI)

ADCT-701

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Malignant Peripheral Nerve Sheath Tumor1 trial

References

Drug Info

Quick Facts

Related News